达尔西利在乳腺癌治疗中的研究进展OA北大核心CSTPCD
Research progress of dalpiciclib in treatment of breast cancer
达尔西利是首个国产原研的细胞周期蛋白依赖性激酶4/6抑制剂,国家药品监督管理局已批准其联合氟维司群或芳香化酶抑制剂治疗激素受体阳性/人表皮生长因子受体2阴性的晚期或转移性乳腺癌.本文主要介绍了达尔西利在乳腺癌中的研究进展,总结药物的作用机制、Ⅰ-Ⅲ期临床试验、以及药物安全性等问题.
As the first domestically originated cell cycle protein-dependent kinase 4/6 inhibitor,dalpiciclib has been approved by the State Drug Ad-ministration for the treatment of hormone recep-tor-positive/human epidermal growth factor recep-tor 2-negative advanced or metastatic breast can-cer in combination with fulvestrant or aromatase inhibitors.This article focuses on the progress of dalpiciclib research in breast cancer,summarizing the drug's mechanism of action,phase Ⅰ-Ⅲ clinical trials,and drug safety issues.
都彩莹;全香花;孙彩红;元海丹
延边大学药学院,延吉 133002,吉林青岛大学附属医院药学部,青岛 266003,山东
临床医学
达尔西利细胞周期蛋白依赖性激酶4/6乳腺癌临床试验
dalpiciclibcyclin-dependent kinase 4/6breast cancerclinical trials
《中国临床药理学与治疗学》 2024 (006)
715-720 / 6
国家自然科学基金(82060674)
评论